Corrigendum
for Daggubati et al., Cardiovasc Res 36 (2) 246-255.
Cardiovascular Research 1999 44(2):452-453; doi:10.1016/S0008-6363(99)00222-9
© 1999 by European Society of Cardiology
Copyright © 1999, European Society of Cardiology
Corrigendum to: "Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators" [Cardiovascular Research 36 (1997) 246–255]
Sreedevi Daggubatia,b,*,
James R. Parksa,b,
Rose M. Overtona,b,
Guillermo Cintrona,b,
Douglas D. Schockena,b and
David L. Veselya,b
aDepartments of Medicine, Physiology and Biophysics, James A. Haley Veterans Hospital, 151, 13000 Bruce B. Downs Blvd., Tampa, FL 33612, USA
bUniversity of South Florida Health Sciences Center, Tampa, FL, USA
* Corresponding author. Tel.: +1-813-9727624; fax: +1-813-9727623
Fig. 1 of the article by Daggubati et al. in Cardiovascular Research 1997;36:246-255 was inadvertently the plotted values for high performance gel permeation chromatography (HP-GPC) of healthy individuals rather than the plotted values of patients with congestive heart failure as shown overleaf.
View larger version (15K):
[in this window]
[in a new window]
[Download PowerPoint slide]
|
Fig. 1 High-performance gel permeation chromatography evidence that (A) atrial natriuretic peptide prohormone (proANP) 1–30, (B) atrial natriuretic peptide prohormone (proANP) 31–67, (C) atrial natriuretic peptide (ANP), and (D) atrial natriuretic peptide prohormone 79–98 exist as separate entities in human congestive heart failure (CHF) plasma. (A) In evaluation of CHF plasma, a sharp peak consistent with proANP 1–98 was observed at 9800 Mr (9.8 kD) together with second peak in fractions 69–72 with proANP 1–30 assay. The pure human synthetic form of proANP 1–30 elutes in fractions 69–70 (arrow). In (B) the elution of proANP 31–67 from CHF plasma was identical with the elution of the pure human synthetic form of proANP 31–67 (arrow). As observed in (B), neither proANP 1–98 nor the ANP prohormone (proANP 1–126) was immunologically recognized in CHF plasma by the proANP 31–67 assay. (C) A distinct elution peak in CHF plasma consisting of 0.3-ml fractions 74–79 with the peak in fraction 75 was found by HP-GPC evaluation followed by ANP radioimmunoassay. (D) Pure synthetic proANP 79–98 (open circles) eluted in 0.3-ml fractions 76–81, with the peak in fraction 78. 125I-labeled proANP 79–98 was similar, with its peak in fraction 79. The elution of proANP 79–98 from CHF plasma was in a peak where the human synthetic form of proANP 79–98 elutes. In addition, two other peaks are observed consistent with (1) proANP 1–98 and (2) proANP 68–98. Elution profiles of molecular weight markers are denoted by arrows on the top of the graph. Vt=total volume collected: Vn=void volume. Each fraction equals 0.3 ml.
|
|
The HP-GPC data for healthy individuals has been published in
Circulation 1994;90:129–140 with a typical HP-GPC plot
of healthy individuals’ plasma and urine also in Peptides
1994;15:861–867.
The authors regret sending the wrong figure and apologize for any confusion caused by this oversight.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
|
|
 
M. J Janse
An odyssee of figures or the importance of proofs
Cardiovasc Res,
August 1, 2002;
55(2):
236 - 237.
[Full Text]
[PDF]
|
|
|
